DCPH Deciphera Pharmaceuticals, Inc.

64.635.87 (+9.99%)
Close: December 13, 2019

Quote

Previous Close
$64.63
Day Range
$58.67-$64.66
52 Week Range
$19.69-$64.66
Volume
672,941
Avg Volume
521,421
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$3.30B
Enterprise Value (EV)
$2.72B
PE Ratio
-
EV/EBITDA
-26.20
Price/Sales
-
Price/Book
11.78
PEG Ratio
0.17

Financials

Revenue
-
Gross Profit
-$317.00K
EBITDA
-$103.78M
EPS, ttm
-$3.95
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
3/25/2020 (102 days)
Debt to Equity
5%
Debt
-
Cash
$293.76M
Net Debt
-

Performance

Beta
1.67
200 Day Moving Avg
$30.95
50 Day Moving Avg
$44.22
52 Week Change
146.59%
YTD Change
197.49%
1 Month Change
34.70%
3 Month Change
77.02%
6 Month Change
201.45%
1 Year Change
146.59%
2 Year Change
229.74%
5 Year Change
232.92%

Share Count

Shares Outstanding
51.0M
Float
31.2M
Restricted Shares
19.8M
Restricted Shares, %
38.80%

Deciphera Pharmaceuticals, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Steven L. Hoerter

Website: http://www.deciphera.com

Description: Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.

Employees: 114

Latest News